Palmetto Peptides Complete Guide to the Research Peptide Semaglutide
IMPORTANT RESEARCH DISCLAIMER: All content on this page is intended strictly for educational and scientific reference purposes. Semaglutide, as offered by Palmetto Peptides, is a research peptide for in vitro laboratory and qualified preclinical research use only. It is not intended for human or veterinary use, consumption, injection, or any clinical application. Palmetto Peptides does not manufacture, sell, or distribute pharmaceutical drugs. Researchers must comply with all applicable federal, state, and local laws and regulations. Nothing on this page constitutes medical advice, clinical guidance, or a claim of therapeutic benefit.
Palmetto Peptides Complete Guide to the Research Peptide Semaglutide
Last Updated: March 19, 2026 | Reading Time: ~18 minutes | Author: Palmetto Peptides Research Team
Quick Answer: Semaglutide is a synthetic GLP-1 receptor agonist peptide with approximately 94% sequence homology to human GLP-1. It is distinguished by its extended plasma half-life (approximately 165 to 184 hours in research models), achieved through albumin binding via a C18 fatty diacid chain and resistance to DPP-4 enzymatic degradation. In preclinical research, it is one of the most studied peptides in the GLP-1 receptor agonist class, making it a valuable tool for laboratories investigating glucose homeostasis, metabolic signaling, and related biological pathways.
Table of Contents
- What Is Semaglutide? An Overview for Researchers
- Molecular Structure and Biochemical Properties
- How Semaglutide Works: GLP-1 Receptor Mechanism
- Semaglutide Research Timeline and Scientific Literature
- Key Research Areas and Preclinical Study Findings
- Semaglutide vs. Related GLP-1 Peptides: A Comparative Overview
- Research-Grade Semaglutide: What to Look For
- Storage, Handling, and Reconstitution Guidelines
- Explore Palmetto Peptides' GLP-1 Peptide Research Catalog
- Supporting Research Articles
- Frequently Asked Questions
- References
1. What Is Semaglutide? An Overview for Researchers
Browse Palmetto Peptides semaglutide research peptide — ≥98% purity, COA verified, available for qualified preclinical research.
Researchers requiring a verified source can find research-grade semaglutide at Palmetto Peptides, supplied with full Certificate of Analysis documentation.
Semaglutide belongs to a class of molecules called glucagon-like peptide-1 (GLP-1) receptor agonists. These are synthetic analogs of the naturally occurring incretin hormone GLP-1, which is secreted from intestinal L-cells in response to food intake. The native hormone plays a well-characterized role in glucose homeostasis, primarily by stimulating insulin secretion in a glucose-dependent manner and suppressing glucagon release.
What makes semaglutide particularly interesting to the research community is not just what it does, but how it was engineered to do it more durably than its predecessors. Native GLP-1 has a plasma half-life measured in minutes, largely because it is rapidly cleaved by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide sidesteps this limitation through two structural innovations that we will explore in detail below.
Since its initial synthesis, semaglutide has become a cornerstone peptide for laboratories studying metabolic signaling, pancreatic beta-cell biology, and cardiometabolic research pathways. Its well-characterized pharmacology makes it an especially useful reference compound in comparative peptide studies.
For qualified researchers sourcing this compound, Palmetto Peptides' semaglutide research peptide is available as a ≥98% purity, COA-verified compound for preclinical laboratory use.
2. Molecular Structure and Biochemical Properties
2.1 Primary Sequence and Key Structural Features
Semaglutide shares approximately 94% sequence homology with native human GLP-1(7-37). The primary sequence is 31 amino acids in length, and two targeted modifications distinguish it from its endogenous counterpart:
Modification 1 (Position 8): Alanine is substituted with alpha-aminoisobutyric acid (Aib). This single substitution creates steric hindrance that prevents DPP-4 from cleaving the peptide at this site, which is the primary pathway of GLP-1 inactivation. The result is dramatically improved proteolytic stability.
Modification 2 (Position 26): A C18 fatty diacid chain is attached to lysine at position 26 via a hydrophilic linker (two OEG [mini-PEG] spacers and a gamma-glutamic acid unit). This fatty acid chain facilitates non-covalent binding to serum albumin in blood, effectively turning albumin into a circulating depot. The peptide is continuously released from albumin in a slow, controlled manner, which is responsible for the extended half-life observed in research models.
2.2 Key Physicochemical Data
| Property | Value |
|---|---|
| Molecular Formula | C187H291N45O59 |
| Molecular Weight | ~4,113.58 g/mol |
| CAS Number | 910463-68-2 |
| Sequence Homology to Human GLP-1 | ~94% |
| Half-Life (Preclinical Models) | ~165 to 184 hours |
| Solubility | Soluble in water and dilute acetic acid |
| Storage Form | Lyophilized powder |
| Recommended Purity (Research Grade) | >98% by HPLC |
2.3 Why Structure Matters for Research
The structural features of semaglutide have direct implications for experimental design. Its albumin-binding mechanism means that researchers must account for protein binding when designing in vitro assays, particularly in serum-free cell culture conditions where albumin concentrations may differ significantly from physiological levels. Its resistance to DPP-4 also makes it a useful comparator when studying DPP-4's role in GLP-1 degradation, since semaglutide's activity is not confounded by this enzymatic variable.
These properties, alongside its thorough characterization in the peer-reviewed literature, are a primary reason the research community continues to reach for semaglutide as a tool compound.
3. How Semaglutide Works: GLP-1 Receptor Mechanism
3.1 The GLP-1 Receptor
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR). It is expressed in a variety of tissues relevant to metabolic research, including pancreatic beta cells, the central nervous system (hypothalamus and brainstem), the heart, kidneys, and gastrointestinal tract. The breadth of GLP-1R expression is part of what makes this receptor system so interesting for multisystem research.
3.2 Receptor Binding and Signal Transduction
When semaglutide binds to GLP-1R, it triggers receptor activation through the canonical Gs protein pathway. The downstream signaling cascade looks like this:
- GLP-1R activation triggers coupling to the stimulatory Gs protein
- Adenylyl cyclase is activated, increasing intracellular cyclic AMP (cAMP)
- Protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC2) are activated
- Downstream effects include modulation of ion channels, gene transcription, and cellular metabolism depending on the tissue type
In pancreatic beta cells specifically, this cascade promotes insulin secretion in a glucose-dependent manner. In hypothalamic neurons, the same pathway has been linked in preclinical models to appetite regulation and energy homeostasis signaling.
3.3 Biased Agonism Considerations
An area of active research involves the concept of biased agonism at the GLP-1R. Some GLP-1 receptor agonists appear to preferentially activate certain downstream pathways (cAMP vs. beta-arrestin recruitment) to different degrees. Understanding where semaglutide falls on this spectrum is an important question for researchers designing mechanistic studies, as pathway bias can influence cellular outcomes independent of binding affinity.
3.4 Downstream Effects Observed in Preclinical Research
The following diagram summarizes the primary GLP-1R signaling pathways studied in preclinical research models:
`
Semaglutide
|
v
GLP-1 Receptor (Class B GPCR)
|
+----> Gs Protein Activation
| |
| v
| Adenylyl Cyclase
| |
| v
| cAMP Increase
| |
| +-----+-----+
| | |
| v v
| PKA EPAC2
| | |
| v v
| Insulin Ion Channel
| Secretion Modulation
|
+----> Beta-arrestin Pathway
|
v
Receptor Internalization
/ Desensitization
`
This signaling architecture is why GLP-1R agonist research has expanded well beyond metabolic biology into cardiovascular, neurological, and renal research domains.
4. Semaglutide Research Timeline and Scientific Literature
A Brief History of Semaglutide in Research
Understanding where semaglutide fits in the broader arc of GLP-1 research helps contextualize its current position as a heavily studied peptide.
2012 - Early pharmacokinetic characterization of semaglutide published, demonstrating superior DPP-4 resistance and extended half-life compared to liraglutide in preclinical models. Marbury et al. published foundational pharmacokinetic data.
2016 - The SUSTAIN clinical trial program (which studied an approved pharmaceutical form of semaglutide) began generating significant data in the published literature, driving increased academic interest in GLP-1R agonist mechanisms and prompting more preclinical mechanistic research.
2018 to 2020 - A surge in preclinical studies using semaglutide as a tool compound to investigate non-pancreatic GLP-1R signaling, particularly in neurological and cardiovascular contexts.
2021 - Publication of preclinical research on central nervous system GLP-1R agonism, with semaglutide used to probe hypothalamic pathways related to energy homeostasis.
2022 to 2024 - Expanded preclinical research programs emerge studying semaglutide in the context of neuroinflammation, hepatic lipid metabolism, and renal function models.
2025 to present - The research community continues to investigate combination peptide approaches, including pairing GLP-1 agonists with GIP agonism (as with tirzepatide), and exploring novel delivery mechanisms that may inform the next generation of research compounds.
Volume of Published Research
The scale of peer-reviewed literature involving GLP-1 receptor agonists, with semaglutide prominently featured, has grown substantially over the past decade:
| Year Range | Approximate PubMed Citations (GLP-1 Receptor Agonists) |
|---|---|
| 2010 to 2014 | ~2,400 |
| 2015 to 2019 | ~6,800 |
| 2020 to 2023 | ~11,200 |
| 2024 to 2025 | ~5,900 (ongoing) |
Source: PubMed search data, approximate values.
This trajectory reflects how central GLP-1 receptor biology has become to metabolic and cardiometabolic research programs worldwide.
5. Key Research Areas and Preclinical Study Findings
5.1 Pancreatic Beta-Cell Biology and Glucose Homeostasis Research
The most extensively characterized preclinical application of semaglutide as a research tool is the study of beta-cell function and glucose regulation. Semaglutide's well-understood GLP-1R agonism makes it a reliable positive control and comparator compound in assays designed to evaluate insulin secretion pathways.
Preclinical studies have used semaglutide to investigate glucose-stimulated insulin secretion (GSIS) mechanisms, beta-cell proliferation signaling, and the interplay between GLP-1R activation and beta-cell apoptosis resistance. A 2020 study by Lingvay et al. in The Lancet reviewed the downstream cellular effects of GLP-1R agonists on pancreatic tissue architecture in preclinical models.
5.2 Cardiovascular and Cardiometabolic Research
GLP-1R expression in cardiac tissue has made semaglutide a useful tool in cardiovascular research programs. Preclinical studies have investigated semaglutide's effects on cardiomyocyte signaling, cardiac inflammatory markers, and vascular endothelial function models.
Research by Husain et al. (2019) in the New England Journal of Medicine (examining pharmaceutical semaglutide) generated significant interest in the GLP-1R agonist mechanism as it relates to cardiovascular endpoints, which has directly stimulated downstream preclinical research using research-grade peptides to examine the cellular mechanisms involved.
5.3 Central Nervous System and Neurological Research
Perhaps the most rapidly expanding preclinical application involves CNS research. GLP-1R is expressed in several brain regions, including the arcuate nucleus of the hypothalamus, the nucleus tractus solitarius, and the ventral tegmental area. Semaglutide has been used in preclinical models to probe appetite-regulating neural circuits, neuroinflammatory pathways, and neuroprotective signaling cascades.
Holst et al. (2022) published a comprehensive review in Physiological Reviews examining GLP-1 receptor agonism in the brain, with semaglutide featured prominently as a high-potency research tool compound due to its CNS penetrance in animal models.
5.4 Hepatic and Lipid Metabolism Research
Liver-focused preclinical research has examined semaglutide's interactions with hepatocyte signaling, lipid synthesis pathways, and hepatic glucose output regulation. Studies have used semaglutide to investigate GLP-1R expression and function in hepatic tissue, a topic of some debate in the literature given the relatively low receptor density in the liver compared to the pancreas.
5.5 Renal Research Models
Emerging preclinical work has explored GLP-1R agonism in renal tissue. Research models have used semaglutide to investigate tubular function, oxidative stress pathways in glomerular cells, and renal inflammatory signaling.
5.6 Summary Table: Preclinical Research Domains
| Research Domain | Primary Tissue/Cell Type | Key Pathway Studied |
|---|---|---|
| Beta-cell biology | Pancreatic beta cells | GSIS, cAMP/PKA, cell survival |
| Cardiovascular | Cardiomyocytes, endothelium | cAMP signaling, inflammation |
| Neuroscience | Hypothalamus, brainstem | Energy homeostasis, neuroinflammation |
| Hepatic metabolism | Hepatocytes | Lipid synthesis, glucose output |
| Renal function | Glomerular, tubular cells | Oxidative stress, inflammation |
6. Semaglutide vs. Related GLP-1 Peptides: A Comparative Overview
Researchers who study GLP-1R agonism often want to understand how semaglutide compares with other available research peptides in the same class. The following is a scientific reference comparison, not a clinical or therapeutic comparison.
6.1 Semaglutide vs. Liraglutide
Liraglutide was the first long-acting GLP-1 analog to be widely adopted as a research tool. Like semaglutide, it uses albumin binding to extend its half-life, but through a C16 fatty acid chain rather than semaglutide's C18 fatty diacid. The result is a shorter half-life (approximately 13 hours for liraglutide vs. 165 to 184 hours for semaglutide) and somewhat lower binding potency at GLP-1R. For researchers designing long-duration preclinical studies, semaglutide's extended half-life makes it useful for reducing dosing frequency in in vivo models.
View our Liraglutide Research Peptide Product Page for specifications.
6.2 Semaglutide vs. Exendin-4
Exendin-4 (also sold as exenatide in pharmaceutical form) is a 39-amino acid peptide originally isolated from the venom of the Gila monster (Heloderma suspectum). It shares approximately 53% sequence homology with human GLP-1 but binds GLP-1R with high affinity. Its distinct structure makes it useful in research contexts where researchers want to study GLP-1R agonism with a non-mammalian peptide scaffold, or when comparing receptor binding kinetics against more humanized analogs like semaglutide.
View our Exendin-4 Research Peptide Product Page for specifications.
6.3 Semaglutide vs. Tirzepatide
Tirzepatide represents the next generation of incretin-based research peptides. Unlike semaglutide (a mono-agonist), tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Its unique activity profile makes it highly valuable in comparative studies examining the additive or synergistic effects of GIP and GLP-1 receptor co-activation. Researchers studying the distinct contributions of each receptor in metabolic signaling often use both semaglutide (pure GLP-1R agonism) and tirzepatide (dual GIP/GLP-1R agonism) in parallel experimental designs.
View our Tirzepatide Research Peptide Product Page for specifications.
6.4 Comparative Quick Reference Table
| Peptide | Receptor Target | Approximate Half-Life (Research Models) | Sequence Homology to Human GLP-1 |
|---|---|---|---|
| Semaglutide | GLP-1R | ~165 to 184 hours | ~94% |
| Liraglutide | GLP-1R | ~13 hours | ~97% |
| Exendin-4 | GLP-1R | ~2.4 hours | ~53% |
| Tirzepatide | GLP-1R + GIPR | ~5 days | Novel dual agonist scaffold |
| Native GLP-1(7-36) | GLP-1R | ~2 minutes | 100% |
7. Research-Grade Semaglutide: What to Look For
Not all research peptides are created equal. For researchers who require reproducible, reliable data, the quality of the starting material is non-negotiable. Here is what distinguishes high-quality, research-grade semaglutide from substandard preparations.
7.1 Purity Verification
Research-grade semaglutide should be verified at greater than 98% purity by high-performance liquid chromatography (HPLC). The HPLC chromatogram should be provided in the Certificate of Analysis (CoA). Any preparation with purity below 95% introduces impurity variables that can confound experimental results, particularly in receptor binding and cell-based assays.
7.2 Mass Spectrometry Confirmation
Beyond HPLC purity, identity confirmation by mass spectrometry (MS) is essential. The molecular ion peak should correspond to the expected molecular weight of 4,113.58 g/mol. Deviations indicate sequence errors, incomplete synthesis, or degradation products.
7.3 Endotoxin Testing
For cell-based and in vivo preclinical research, endotoxin contamination is a serious concern. Lipopolysaccharide (LPS) endotoxins from bacterial contamination can activate inflammatory pathways that confound results, particularly in immune cell or CNS tissue research. Reputable suppliers test for endotoxins using the Limulus Amebocyte Lysate (LAL) assay.
7.4 Certificate of Analysis (CoA)
Every lot of research-grade semaglutide should come with a lot-specific CoA documenting:
- HPLC purity percentage
- MS identity confirmation
- Peptide content (net peptide content, accounting for water and counter-ion content)
- Endotoxin levels (when applicable)
- Storage recommendations
- Expiration/retest date
At Palmetto Peptides, every product ships with a full CoA. You can view and download lot-specific CoAs directly from our Semaglutide Product Page.
7.5 Synthesis Method Matters
Semaglutide's structural complexity, particularly the fatty acid chain conjugation, means that solid-phase peptide synthesis (SPPS) alone is insufficient. The fatty diacid moiety requires specialized conjugation chemistry. Researchers should confirm that their supplier has validated conjugation protocols, not just linear peptide synthesis capabilities.
8. Storage, Handling, and Reconstitution Guidelines
Proper peptide handling is critical to maintaining research integrity. Semaglutide, like all research peptides, can degrade if handled incorrectly. The following guidelines are intended for qualified laboratory researchers.
8.1 Lyophilized Storage
- Store lyophilized semaglutide at -20°C, protected from light and moisture
- Do not expose to repeated temperature fluctuations before reconstitution
- Keep sealed in original vial with desiccant until ready to use
- Typical shelf life of lyophilized peptide: 24 months when stored correctly
8.2 Reconstitution Protocol
- Recommended diluents: sterile distilled water, 0.9% saline, or dilute acetic acid (0.1M to 1% v/v)
- Note: Due to its fatty acid chain, semaglutide has relatively low solubility in plain water. Adding a small percentage of acetic acid (typically 0.5 to 1%) or using a PBS solution at physiological pH generally improves solubility
- Reconstitute gently by rolling the vial; avoid vigorous vortexing, which can cause aggregation
- Allow to sit at room temperature for 5 to 10 minutes if needed for full dissolution
- Once reconstituted, aliquot into single-use portions to avoid freeze-thaw cycles
8.3 Reconstituted Storage
- Store reconstituted aliquots at -80°C for long-term storage (up to 3 months)
- For short-term use (within 7 days), store at 4°C
- Avoid repeated freeze-thaw cycles, as these promote aggregation and degradation
- Do not store reconstituted peptide at room temperature for extended periods
8.4 Working Concentrations in Research
Standard working concentrations used in published preclinical research vary widely by application, from nanomolar concentrations in receptor binding assays to micromolar concentrations in certain in vitro cell-based models. Researchers should consult the primary literature for their specific assay context. Palmetto Peptides does not provide dosing guidance for human or veterinary use.
9. Explore Palmetto Peptides' GLP-1 Research Catalog
Palmetto Peptides offers a curated selection of high-purity GLP-1 axis research peptides for qualified laboratory researchers. All products are manufactured to research-grade specifications, ship with lot-specific CoAs, and are sold exclusively for in vitro and preclinical research use.
Featured GLP-1 Research Peptides
- Semaglutide Research Peptide - GLP-1R agonist, >98% purity, C18 fatty diacid conjugated
- Tirzepatide Research Peptide - Dual GIP/GLP-1R agonist, novel incretin mimetic scaffold
- Liraglutide Research Peptide - GLP-1R agonist, C16 fatty acid, ~13-hour half-life model
- Exendin-4 Research Peptide - GLP-1R agonist, non-mammalian scaffold, 39 amino acids
- GLP-1(7-36) Amide Research Peptide - Native human incretin hormone, unmodified
Related Metabolic Research Peptides
- Insulin Research Peptide - Related to GLP-1R downstream effects on glucose homeostasis pathways
- Glucagon Research Peptide - GLP-1's counterpart in alpha-cell biology research
- GIP (Glucose-Dependent Insulinotropic Polypeptide) - The complementary incretin to GLP-1, co-targeted by tirzepatide
All Palmetto Peptides products are strictly for qualified research use only. Not for human or veterinary use. Must be purchased by and used by qualified researchers in appropriate laboratory settings.
10. Supporting Research Articles
For deeper reading on specific aspects of semaglutide and GLP-1R biology, see the following supporting articles from the Palmetto Peptides Research Library:
- GLP-1 Receptor Agonists in Preclinical Metabolic Research: A Mechanism Overview
- Comparing GLP-1 Peptide Half-Lives: Why Duration Matters in Research Models
- Reconstituting and Storing Research Peptides: Best Practices for the Laboratory
- GLP-1R Expression in the Brain: What Preclinical Research Tells Us
- Understanding Certificates of Analysis for Research Peptides
- Tirzepatide vs. Semaglutide in Research: Dual vs. Single Receptor Agonism
- The Role of DPP-4 Resistance in GLP-1 Analog Design
- Pancreatic Beta-Cell Research Models and GLP-1 Receptor Agonists
11. Frequently Asked Questions
What is semaglutide?
Semaglutide is a synthetic 31-amino acid peptide and glucagon-like peptide-1 (GLP-1) receptor agonist with approximately 94% sequence homology to human GLP-1. It is distinguished by its C18 fatty diacid chain (enabling albumin binding) and a DPP-4-resistant substitution at position 8. In the research context, it is a widely used tool compound for studying GLP-1 receptor signaling and metabolic pathways in vitro and in preclinical models.
What is the molecular weight of semaglutide?
The molecular weight of semaglutide is approximately 4,113.58 g/mol, with a molecular formula of C187H291N45O59 and CAS number 910463-68-2.
How does semaglutide differ from native GLP-1?
Native GLP-1(7-36) amide has a plasma half-life of approximately 2 minutes and is rapidly inactivated by DPP-4 cleavage. Semaglutide circumvents this through two structural modifications: a position-8 substitution that confers DPP-4 resistance, and a fatty diacid chain at position 26 that enables reversible albumin binding. Together, these modifications extend the half-life to approximately 165 to 184 hours in research models, a roughly 5,000-fold improvement over the native peptide.
Is semaglutide available for research purposes?
Yes. Semaglutide is available as a research-grade peptide for in vitro laboratory and qualified preclinical research use. Palmetto Peptides provides research-grade semaglutide with greater than 98% purity, verified by HPLC and mass spectrometry, with lot-specific certificates of analysis. It is not intended for human or veterinary use.
What receptors does semaglutide bind to?
Semaglutide selectively binds to the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor. It does not meaningfully interact with GIP receptors, glucagon receptors, or other incretin receptors at standard research concentrations, which distinguishes it from dual agonists like tirzepatide.
How should semaglutide be stored in a research setting?
Lyophilized semaglutide should be stored at -20°C, protected from light and moisture, in a sealed vial. After reconstitution with sterile water or dilute acetic acid, aliquots should be stored at -80°C for up to 3 months or at 4°C for short-term use (up to 7 days). Repeated freeze-thaw cycles should be avoided.
What is the expected purity of research-grade semaglutide?
High-quality research-grade semaglutide should have purity greater than 98% as verified by HPLC analysis, with identity confirmed by mass spectrometry. Palmetto Peptides provides a lot-specific CoA with every order documenting these specifications.
What GLP-1 related peptides are commonly studied alongside semaglutide?
Researchers frequently study semaglutide in parallel with tirzepatide (dual GIP/GLP-1R agonist), liraglutide (earlier GLP-1 analog with shorter half-life), exendin-4 (non-mammalian GLP-1R agonist scaffold), and native GLP-1(7-36) amide to compare binding kinetics, signaling bias, and receptor occupancy dynamics.
Does Palmetto Peptides sell semaglutide for human use?
No. Palmetto Peptides sells semaglutide strictly as a research peptide for qualified in vitro and preclinical laboratory use. It is not intended for human or veterinary administration, and it is not sold for any clinical, therapeutic, or diagnostic purpose.
12. References
The following peer-reviewed publications represent key sources in the scientific literature on semaglutide and GLP-1 receptor agonism. They are provided for educational reference purposes for qualified researchers.
- Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. https://doi.org/10.1021/acs.jmedchem.5b00726
- Marbury TC, Flint A, Jacobsen JB, Derving Karsbøl J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clinical Pharmacokinetics. 2017;56(11):1381-1390. https://doi.org/10.1007/s40262-017-0528-2
- Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2019;381(9):841-851. https://doi.org/10.1056/NEJMoa1901118
- Lingvay I, Desouza CV, Lalic KS, et al. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin. Diabetes Care. 2018;41(9):1926-1937. https://doi.org/10.2337/dc17-2381
- Holst JJ, Rosenkilde MM. GLP-1 as a target in obesity treatment - what are the issues? Nature Reviews Endocrinology. 2022;18(7):421-435. https://doi.org/10.1038/s41574-022-00661-0
- Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism. 2022;57:101351. https://doi.org/10.1016/j.molmet.2021.101351
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021;46:101102. https://doi.org/10.1016/j.molmet.2020.101102
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. https://doi.org/10.1172/jci.insight.140532
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology. 2019;10:155. https://doi.org/10.3389/fendo.2019.00155
- Muller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019;30:72-130. https://doi.org/10.1016/j.molmet.2019.09.010
Legal and Compliance Notices
FDA Compliance Statement: Semaglutide peptide as sold by Palmetto Peptides is offered strictly for research use and is not an FDA-approved drug, dietary supplement, or medical device. It is not intended for human or veterinary use, consumption, or administration. Palmetto Peptides does not make any therapeutic claims regarding semaglutide or any research peptide.
Research Use Only: All products sold by Palmetto Peptides are for in vitro laboratory and qualified preclinical research use only. Purchasers assume full responsibility for compliance with all applicable local, state, federal, and international regulations governing the purchase, use, and handling of research chemicals and peptides.
No Medical Advice: Nothing on this page constitutes medical advice, clinical guidance, or a recommendation for any therapeutic application. Researchers should consult the primary scientific literature and their institutional review processes before designing any research protocol.
Not for Resale or Human Use: Palmetto Peptides products are not for resale to the general public and are not intended for human or animal administration of any kind.
Last Updated: March 19, 2026
Author: Palmetto Peptides Research Team
Palmetto Peptides | Research Peptides for Qualified Researchers | palmettopeptides.com